A novel integrated system using patient-derived glioma cerebral organoids and xenografts for disease modeling and drug screening
Liyang Zhang(Central South University), Zhixiong Liu(Central South University), Jingxuan Yang(Kunming University of Science and Technology), Quan Cheng(Central South University), Junxia Zhang(Shaoyang University), Fangkun Liu(Central South University), Yongjian Tang(Central South University), Jun Peng(Fudan University Shanghai Cancer Center), Zailong Qin(Guangxi Maternal and Child Health Hospital), Fan Fan(Nanjing University of Chinese Medicine), Min Li(Xinjiang Medical University), Yusheng Li(Central South University), Zhongliang Hu(Central South University), Weihua Liao(Central South University), Ping Hu(Central South University), Yu Zeng(Beihang University), Nathaniel Weygant(Fujian University of Traditional Chinese Medicine), Fengqiong He(Central South University), Anliu Tang(Central South University)
Cited by 52
Related Papers
Glioma targeted therapy: insight into future of molecular approaches
|Molecular Cancer|2022|727
CGCG clinical practice guidelines for the management of adult diffuse gliomas
|Cancer Letters|2016|650
PARP inhibitor resistance: the underlying mechanisms and clinical implications
|Molecular Cancer|2020|548
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
|Journal of Experimental & Clinical Cancer Research|2021|535
Clinical practice guidelines for the management of adult diffuse gliomas
|Cancer Letters|2020|482